Comment on Survey Specimen B9 Microbiology

Similar documents
Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing

European Committee on Antimicrobial Susceptibility Testing

Intrinsic, implied and default resistance

EUCAST recommended strains for internal quality control

Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016

Routine internal quality control as recommended by EUCAST Version 3.1, valid from

European Committee on Antimicrobial Susceptibility Testing

2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine

Aberdeen Hospital. Antibiotic Susceptibility Patterns For Commonly Isolated Organisms For 2015

Help with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST

2015 Antibiotic Susceptibility Report

2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose

2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services

Antibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting

2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose

جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی

THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS

Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities.

MICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC

2016 Antibiotic Susceptibility Report

Chemotherapy of bacterial infections. Part II. Mechanisms of Resistance. evolution of antimicrobial resistance

QUICK REFERENCE. Pseudomonas aeruginosa. (Pseudomonas sp. Xantomonas maltophilia, Acinetobacter sp. & Flavomonas sp.)

The β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018

Service Delivery and Safety Department World Health Organization, Headquarters

ESBL- and carbapenemase-producing microorganisms; state of the art. Laurent POIREL

INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER

CONTAGIOUS COMMENTS Department of Epidemiology

ADC 2016 Report on Bacterial Resistance in Cultures from SEHOS and General Practitioners in Curaçao

C&W Three-Year Cumulative Antibiogram January 2013 December 2015

Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory

EARS Net Report, Quarter

Cipro for gram positive cocci in urine

Concise Antibiogram Toolkit Background

Bacterial Pathogens in Urinary Tract Infection and Antibiotic Susceptibility Pattern from a Teaching Hospital, Bengaluru, India

Childrens Hospital Antibiogram for 2012 (Based on data from 2011)

Susceptibility Testing and Resistance Phenotypes Detection in Bacterial Pathogens Using the VITEK 2 System

Mechanism of antibiotic resistance

Antimicrobial Stewardship Strategy: Antibiograms

Antimicrobial Susceptibility Testing: The Basics

Microbiology. Multi-Drug-Resistant bacteria / MDR: laboratory diagnostics and prevention. Antimicrobial resistance / MDR:

ANTIMICROBIAL SUSCEPTIBILITY CONTEMPORARY SUSCEPTIBILITY TESTS AND TREATMENTS FOR VRE INFECTIONS

Antimicrobial Susceptibility Patterns

January 2014 Vol. 34 No. 1

Antimicrobial Resistance Surveillance from sentinel public hospitals, South Africa, 2013

Understanding the Hospital Antibiogram

CONTAGIOUS COMMENTS Department of Epidemiology

ESCMID Online Lecture Library. by author

Super Bugs and Wonder Drugs: Protecting the One While Respecting the Many

Antimicrobial Susceptibility Testing: Advanced Course

Antimicrobial Resistance Strains

Main objectives of the EURL EQAS s

GENERAL NOTES: 2016 site of infection type of organism location of the patient

What s new in EUCAST methods?

Antimicrobial susceptibility

Detection of ESBL Producing Gram Negative Uropathogens and their Antibiotic Resistance Pattern from a Tertiary Care Centre, Bengaluru, India

Interactive session: adapting to antibiogram. Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe

ESCMID Online Lecture Library. by author

Mili Rani Saha and Sanya Tahmina Jhora. Department of Microbiology, Sir Salimullah Medical College, Mitford, Dhaka, Bangladesh

Microbiology ( Bacteriology) sheet # 7

Other Beta - lactam Antibiotics

BactiReg3 Event Notes Module Page(s) 4-9 (TUL) Page 1 of 21

CONTAGIOUS COMMENTS Department of Epidemiology

21 st Expert Committee on Selection and Use of Essential Medicines Peer Review Report Antibiotics Review

Leveraging the Lab and Microbiology Department to Optimize Stewardship

Compliance of manufacturers of AST materials and devices with EUCAST guidelines

Prevalence of Extended Spectrum Beta- Lactamase Producers among Various Clinical Samples in a Tertiary Care Hospital: Kurnool District, India

There are two international organisations that set up guidelines and interpretive breakpoints for bacteriology and susceptibility

Educating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges

Michael Hombach*, Guido V. Bloemberg and Erik C. Böttger

EDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update

PROTOCOL for serotyping and antimicrobial susceptibility testing of Salmonella test strains

Should we test Clostridium difficile for antimicrobial resistance? by author

2010 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Children s Hospital

Tel: Fax:

SMART WORKFLOW SOLUTIONS Introducing DxM MicroScan WalkAway System* ...

Antimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018

2009 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Childrens Hospital

VLLM0421c Medical Microbiology I, practical sessions. Protocol to topic J05

Int.J.Curr.Microbiol.App.Sci (2018) 7(8):

Microbiology Basics and Applications to Clinical Practice

Performance Information. Vet use only

Secondary peritonitis

New Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs

Antibiotic Updates: Part II

Antimicrobial Resistance Trends in the Province of British Columbia

EUCAST Subcommitee for Detection of Resistance Mechanisms (ESDReM)

Management of Native Valve

Clinico-Microbiological Profile of Urinary Tract Infection in Tertiary Care Hospital in Ahmedabad, Gujarat, India

Interpreting Microbiology reports for better Clinical Decisions Interpreting Antibiogrammes

Compliance of manufacturers of AST materials and devices with EUCAST guidelines

INCIDENCE OF BACTERIAL COLONISATION IN HOSPITALISED PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS

CUMULATIVE ANTIBIOGRAM

a. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.

CONTAGIOUS COMMENTS Department of Epidemiology

ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat

Antibacterial therapy 1. د. حامد الزعبي Dr Hamed Al-Zoubi

Taiwan Surveillance of Antimicrobial Resistance (TSAR)

RESISTANT PATHOGENS. John E. Mazuski, MD, PhD Professor of Surgery

Safe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times

5/4/2018. Multidrug Resistant Organisms (MDROs) Objectives. Outline. Define a multi-drug resistant organism (MDRO)

Transcription:

Verein für medizinische Qualitätskontrolle Association pour le contrôle de Qualité medical Associazione per il controllo di qualità medico Comment on Survey Specimen B9 Microbiology 2014-1 Specimen A: Midstream urine / susceptibility testing This is a strain of Escherichia coli with an extended spectrum beta lactamase (ESBL). Cefepime and cefotaxime were resistant (we accepted all results for ceftazidime), but amoxicillin/clavulanic acid and piperacillin/tazobactam were sensitive; per EUCAST, a change to resistant also according to CLSI is not warranted. In 2014, EUCAST changed the clinical limits for amoxicillin/clavulanic acid for uncomplicated urinary tract infections: for MIC from 8 to currently 32 mg/l; for the disc test (20μg amoxicillin 10μg clavulanic acid) from 17 mm to currently 16 mm. The MIC limit values for other infections remained at 8, but for the disc test the limit value of 17 was increased to 19 mm. This change in the limits in particular the different limits for urinary tract infections and other infections is problematic for many reasons; the Swiss Antibiogram Committee will address these and provide a suggestion to the laboratories on how to handle this. This strain was intermediately sensitive to ertapenem (MIC 1 mg/l). We accepted all the results. Increasingly, we see ESBL, where (similar to AmpC producers, see discussion 2013 4 specimen A) changes of porins in the outer cell membrane and overexpression of efflux pumps may result in reduced sensitivity to ertapenem. Cefoxitin should not be reported in the microbiology report because cefoxtin is intended only for AmpC screening; this time we did not evaluate cefoxitin. Cefoxitin is on the select quality control list because of staphylococci. In future, we will ignore cefoxitin reports; please ensure that you have specified enough of the other antibiotics. Fosfomycin and nitrofurantoin were sensitive; in accordance with EUCAST, MIC is in principle required for fosfomycin, but the evaluation of inhibitors is in preparation. We would like to remind you that for Enterobacteriacea you have the possibility of distinguishing between complicated mechanisms (ESBL or hyperproduction of AmpC in combination with membrane changes) and carbapenemases by contacting one of the expert laboratories designated by the Swiss Antibiogram Committee. We included the appropriate form at our last discussion, which can also found on the homepage of the Schweizerische Gesellschaft für Mikrobiologie (Swiss Society for Microbiology) (www.swissmicrobiology.ch); please contact the corresponding specialized laboratory in advance to clarify the exact procedure. Escherichia coli 65

MQ Commentary to Survey 2014-1 B9 Seite 2/5 Specimen B: Urinary Tract Infection / susceptibility testing Enterococcus faecium isolated from this urinary tract infection exhibits high level gentamicin resistance. As also discussed in the last meeting [regarding] 2013 4 specimen B, enterococci always present low level resistance to aminoglycosides, therefore the presence of so called high level resistance in enterococci is of interest. We ask that in future you report only high level resistance in enterococci; the sole indication of resistance to aminoglycosides is not considered in the evaluation; therefore, in that case, your number of reported antibiotics might not be insufficient. The same applies to reports regarding cephalosporins and clindamycin; reporting resistance to clindamycin and cephalosporins in enterococci is not wrong, but it is a natural resistance. For nitrofurantoin, EUCAST lists only one value for Enterococcus faecalis, but not for Enterococcus faecium. This time we accepted all results, but in the future will evaluate them as incorrect. However, we evaluated the reported results for fosfomycin, tetracycline, and doxycycline as wrong in accordance with our announcement at the meeting 2013 4 Specimen B. Enterococcus faecium 63 Enterococcus sp. 1 Enterococcus gallinarum 1 Specimen C: Sepsis The genus Aerococcus includes seven different species. They are facultative anaerobic, catalasenegative, Gram positive cocci, which frequently form tetrads in liquid medium. Aerococcus urinae and Aerococcus sanguinicola can both cause urinary tract infections (Cattoir et al. 2010. Aerococcus urinae and Aerococcus sanguinicola, two frequently misidentified uropathogens, Scand J Infect Dis 42: 775 780). Since they are both resistant to ciprofloxacin, they can proliferate on this treatment regimen and sometimes migrate into the blood and cause sepsis (rarely endocarditis); unlike Aerococcus viridans, both are sensitive to penicillin. They are frequently misidentified as A. viridans (M. Rasmussen 2013. Aerococci and aerococcal infections. J Infect 66: 467 474) since A. urinae and A. sanguinicola are not included in all commercial databases. However, penicillin sensitivity indicates this error regarding the identification of A. viridans. Conventional reactions such as the pyrrolidonylarylamidase (PYR), leucine aminopeptidase (LAP), and beta glucuruonidase (BGUR) can differentiate the above species from each other. A. viridans and A. sanguinicola are PYR positive (A. urinae and other aerococci are PYR negative); A. urinae and A. sanguinocola are LAP positive (A. viridans is LAP negative); A. urinae, A. sanguinicola, and occasionally A. viridans are BGUR positive (other aerococci are BGUR negative) (M. Rasmussen 2013). Our strain is A. sanguinocola (PYR, LAP, BGUR all positive). MALDI TOF MS identifies A. sanguicola and A. urinae (E. Seenebey et al. 2013. Matrix assisted laser desorption ionization time of flight mass spectrometry is a sensitive and specific method for identification of aerococci. J Clin Microbiol 51: 1303 4). Aerococcus sanguinicola 23 Aerococcus sp. 29 Aerococcus viridans 11 Aerococcus urinae 1 Pilze 1

MQ Commentary to Survey 2014-1 B9 Seite 3/5 Specimen D: Ascites with intestinal perforation Bacteroides fragilis was isolated from this ascites specimen following intestinal perforation. It was isolated from various materials, mostly in the context of gastrointestinal clinic (post operative wound infections, perforated colon, etc.). B. fragilis is the anaerobic, Gram negative rod bacteria most frequently isolated in the laboratory. B. fragilis is distinguished by growth on bile containing agar (resistant to bile), and by positive esculin reaction. Catalase positive and indole reaction is negative. B. fragilis is resistant to vancomycin (5 µg, kanamycin (1000 µg) and colistin (10 µg); this diagnostic resistance points to the B. fragilis group. Commercial systems allowed an accurate diagnosis. From glucose, B. fragilis typically produces acetic acid, little propionic acid, succinate, isobutyric acid, and isovaleric acid. B. fragilis is also readily identified to the species level by MALDI TOF MS. Bacteroides fragilis 55 Bacteroides sp. 1 Bacteroides stercoris 2 Gram negative rods 2 No growth 1 Microbacterium sp. 1 Prevotella sp. 1 Escherichia coli 1 Alistipes putredinis 1 Specimen E: Sinusitis in dog owners We have not rated this specimen. We wanted to introduce Staphylococcus pseudointermedius with the specimen. For resistance testing with cefoxitin, the EUCAST guidelines of 2014 list S. pseudointermedius separately; when screening with cefoxitin, the resistance circle must be 35 mm for oxacillin sensitivity to be assumed (representative of penicillinase resistant penicillins and cephalosporins). S. pseudointermedius was first described in 2005 in animals (Devriese et al. 2005. Staphylococcus pseudointermedius sp. nov., a coagulase positive species from animals. Int J Evol Microbiol 2005; 55: 1569 73). S. pseudointermedius is clumping factor negative, but coagulase positive, and may also form hemolysins, exfoliatins, enterotoxins, and leukocidins similar to PVL with S. aureus. The methicillinresistant S. pseudointermedius has a similar meaning in dog as MRSA in humans. Humans can also become infected by contact with dogs, which is what we wanted to demonstrate with this strain. (Stegmann et al. 2010. Human infection associated with methicillin resistant Staphylococcus pseudointermedius ST71. J Antimicrob Chemother 65:2047 8). Differentiation to Staphylococcus intermedius cannot be unequivocally made with conventional tests and MALDITOF, but with 16S RNA gene sequencing. Most isolates of dogs are S. pseudointermedius.

MQ Commentary to Survey 2014-1 B9 Seite 4/5 The importance of human S. pseudointermedius strains and their genetic characteristics are largely unknown. In order to investigate these properties in more detail, Professor Vincent Perreten of the Institut für Veterinärbakteriologie (Institute of Veterinary Bacteriology) is very keen for you to send him S. pseudointermedius strains you may have isolated in your laboratory. Also, strains with questionable identities or unclear phenotype of methicillin resistance can be mailed for further identification. Please send your S. pseudointermedius strains to the following address: Vincent Perreten, Prof. Dr. Institut für Veterinär Bakteriologie Universität Bern PO Box Länggass Strasse 122 CH 3001 Bern Phone: +41 31 631 2484 Fax: +41 31 631 2634 vincent.perreten@vetsuisse.unibe.ch Staphylococcus intermdius 31 Staphylococcus pseudointermedius 32 Gram positive Kokken 1 Staphylococcus xylosus 1 Best Regards Prof. Dr. R. Zbinden F.S. Hufschmid-Lim

MQ Commentary to Survey 2014-1 B9 Seite 5/5 Susceptibility Testing Sample A Susceptibility Testing Sample B Institut für Klinische Chemie Universitätsspital Zürich CH-8091 Zürich Telefon 044 255 34 11 Fax 044 261 12 83 www.mqzh.ch info@mqzh.ch